BioCentury | Apr 15, 2013
Company News

LeukoSite board of directors update

...LeukoSite Inc. , Cambridge, Mass. Business: Infectious diseases/AIDS Appointed: Mark Skaletsky, president and CEO of GelTex Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...parathyroid hormone levels, but when used with calcium-based phosphate binders it can lead to hypercalcemia. GelTex Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...levels. No adverse events occurred. The company plans an NDA submission in the fourth quarter. GelTex Pharmaceuticals Inc....
BioCentury | Feb 21, 2011
Strategy

BioMarin wants control

...biotech's Renagel sevelamer hydrochloride for hyperphosphatemia. Rights to the latter were obtained in 1997 from GelTex Pharmaceuticals Inc....
BioCentury | Apr 11, 2005
Finance

Ebb & Flow

...diarrhea (see B15). GENZ gained the non-antibiotic, polymer-based toxin absorber from its 2000 acquisition of GelTex...
BioCentury | May 17, 2004
Product Development

All in the family

...GT389-255, a dual lipase inhibitor and fat binder, has snaked its way through GelTex Pharmaceuticals Inc. and Genzyme...
...divests a previously acquired asset that lies outside its strategic focus. The compound originated at GelTex...
...compound is coming full circle for Peptimmune CEO Robert Carpenter, who was formerly chairman of GelTex...
BioCentury | Sep 1, 2003
Strategy

Genzyme: Minimizing dilution

...100. A. 9/11/00 - GelTex announcement (GENZ 9/8/00 mkt cap = $5.5B) B. 12/14/00 - GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
BioCentury | Sep 1, 2003
Strategy

Millennium: Assumptions matter

...B. 2/12/02 - Cor acquisition completed C. 8/22/03 - MLNM mkt cap = $3.9B Table: Genzyme-GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
BioCentury | Sep 1, 2003
Strategy

Versicor: Keeping control

...at the same time. Versicor’s purchase of Biosearch bears some resemblance to GENZ’s acquisition of GelTex...
BioCentury | Sep 1, 2003
Strategy

Back to School 2003: The M&A game

...Pharmaceuticals Inc.’s acquisition of Cor Therapeutics Inc. for $1.2 billion in stock, Genzyme’s acquisition of GelTex Pharmaceuticals Inc....
Items per page:
1 - 10 of 167
BioCentury | Apr 15, 2013
Company News

LeukoSite board of directors update

...LeukoSite Inc. , Cambridge, Mass. Business: Infectious diseases/AIDS Appointed: Mark Skaletsky, president and CEO of GelTex Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...parathyroid hormone levels, but when used with calcium-based phosphate binders it can lead to hypercalcemia. GelTex Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...levels. No adverse events occurred. The company plans an NDA submission in the fourth quarter. GelTex Pharmaceuticals Inc....
BioCentury | Feb 21, 2011
Strategy

BioMarin wants control

...biotech's Renagel sevelamer hydrochloride for hyperphosphatemia. Rights to the latter were obtained in 1997 from GelTex Pharmaceuticals Inc....
BioCentury | Apr 11, 2005
Finance

Ebb & Flow

...diarrhea (see B15). GENZ gained the non-antibiotic, polymer-based toxin absorber from its 2000 acquisition of GelTex...
BioCentury | May 17, 2004
Product Development

All in the family

...GT389-255, a dual lipase inhibitor and fat binder, has snaked its way through GelTex Pharmaceuticals Inc. and Genzyme...
...divests a previously acquired asset that lies outside its strategic focus. The compound originated at GelTex...
...compound is coming full circle for Peptimmune CEO Robert Carpenter, who was formerly chairman of GelTex...
BioCentury | Sep 1, 2003
Strategy

Genzyme: Minimizing dilution

...100. A. 9/11/00 - GelTex announcement (GENZ 9/8/00 mkt cap = $5.5B) B. 12/14/00 - GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
BioCentury | Sep 1, 2003
Strategy

Millennium: Assumptions matter

...B. 2/12/02 - Cor acquisition completed C. 8/22/03 - MLNM mkt cap = $3.9B Table: Genzyme-GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
...Consolidate and accelerate sales of Renagel and gain GelTex’s product development engine DISPOSITION OF ASSETS GelTex...
BioCentury | Sep 1, 2003
Strategy

Versicor: Keeping control

...at the same time. Versicor’s purchase of Biosearch bears some resemblance to GENZ’s acquisition of GelTex...
BioCentury | Sep 1, 2003
Strategy

Back to School 2003: The M&A game

...Pharmaceuticals Inc.’s acquisition of Cor Therapeutics Inc. for $1.2 billion in stock, Genzyme’s acquisition of GelTex Pharmaceuticals Inc....
Items per page:
1 - 10 of 167